The global respiratory inhaler devices market is on the cusp of significant transformation over the next decade, driven by a rising incidence of respiratory diseases, technological advancements, and ...

A shuttered Milanese manufacturing site with a storied history is getting a new lease on life, thanks to a nearly ...

Innovata Biomed Ltd has developed an alternative device, the Clickhaler®, which is a multiple-dose dry powder inhaler (DPI). The present study compared patient acceptability of the salbutamol ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...

Italian biopharma Chiesi Group has announced a major investment in Nerviano, near Milan, with the building of a new facility ...

And while other options exist like dry-powder inhalers and soft mist inhalers, MDIs are still the best option for many patients for a variety of reasons, according to AstraZeneca. AstraZeneca and ...

De Motu Cordis Pty Ltd (DMC) has been developing its simple, single-use inhaler, about the size of a pencil sharpener, that is designeddeliver adrenaline in a fine dry powder form. Pulling the red ...

In this video, Andrea Pappalardo, MD, discusses the developments in targeted therapies and technologies for pediatric asthma.

including soft mist inhalers (SMIs), pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), nebulizers, nasal sprays, and ophthalmic products for both small and biologic molecules.